Uncategorized

Biotech’s China problem: An issue of national security or economic value for the US?

Published

on

Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version